Two Mount Sinai studies show how APOE4 turns key blood-vessel support cells into scar-forming cells, and that blocking one signal restored vessels in aged mice. It is early science with a clear lead.
Both promise to spot signs of dozens of cancers from a single blood draw, and neither is FDA-approved yet. Here is how they differ on what they measure, how often they raise false alarms, what happens after a positive result, and cost.
Both are once-daily GLP-1 tablets for weight loss, and both start at $149 a month. But they are very different drugs — and the differences in how you take them, how much weight people lost, and what higher doses cost are worth knowing.
Sefaxersen significantly cut a key marker of kidney damage in a rare disease that has suddenly attracted a wave of new treatments — and Roche is betting a once-monthly, at-home injection can stand out.
A plain-language guide to Berger’s disease — what goes wrong in the kidneys, how it is found, why it is more serious than once thought, and how a wave of new drugs has changed treatment.
An FDA advisory panel voted that the benefits of Grail’s Galleri outweigh its risks — but a split vote on effectiveness, and a missed goal in a major UK trial, show how much is still unsettled.
A quiet FDA rule change — letting bone-density scans stand in for fractures in trials — is reigniting drugmaker and investor interest in a common disease that had fallen out of fashion.
In a rare joint letter, the chairs of Europe’s biggest drugmakers say the continent’s share of pharmaceutical research and investment is sliding — and urge governments to act before the decline becomes permanent.
The deal for a preclinical radioligand therapy deepens Novartis’s lead in targeted radioactive cancer treatment — and adds to a rush of Western pharma licensing innovative assets from China.
Envisagenics uses machine learning to mine “RNA splicing” — a largely untapped source of cancer targets — and Boehringer Ingelheim is paying up to $1 billion to turn those targets into precision therapies.
Basecamp Research trained a biological “foundation model” on the world’s largest proprietary gene dataset — and wants to use it to design therapies that reprogram a patient’s own cells inside the body.
Veterans who came off GLP-1 medications faced a rising risk of heart attack, stroke and death — up 22% after two years — suggesting the drugs’ cardiovascular protection fades fast once you stop.